Skip to main content
Wolfe Building Exterior

JHDAAI Team

Project Team

Gerard Anderson

Gerard Anderson, PhD

Gerard Anderson is a Professor of Health Policy and Management and Professor of International Health at the Bloomberg School of Public Health, Professor of Medicine at the Johns Hopkins University School of Medicine, and Director of the Johns Hopkins Center for Hospital Finance and Management.  He directs the JHDAAI and has published more than 300 peer-reviewed articles, testified in Congress more than 50 times as an individual witness, and serves on multiple editorial committees.  Prior to his arrival at Johns Hopkins, Anderson held various positions in the Office of the Secretary, U.S. Department of Health and Human Services, where he helped to develop Medicare prospective payment legislation.

ganderson@jhu.edu

Caleb Alexander

Caleb Alexander, MD

Caleb Alexander is a Professor of Epidemiology and Medicine at the Bloomberg School of Public Health, where he serves as founding co-director of the Center for Drug Safety and Effectiveness and Principal Investigator of the Johns Hopkins-FDA Center of Excellence in Regulatory Science and Innovation. He is a practicing general internist and pharmacoepidemiologist and is internationally recognized for his research examining prescription drug utilization, safety and effectiveness. The author of more than 375 scientific articles and book chapters, many of which have focused on the epidemiology of the opioid epidemic, he has published regularly in leading scientific journals and testified before expert bodies including the U.S. House of Representatives and U.S. Senate. Alexander also serves on several editorial and advisory boards and is a frequent speaker on pharmaceutical utilization and policy. He received his BA cum laude from the University of Pennsylvania, an MD from Case Western Reserve University, and an MS from the University of Chicago. Alexander’s research interests include prescription drugs; drug utilization; drug safety; drug effectiveness; pharmacoepidemiology, and pharmaceutical policy.

galexan9@jhmi.edu

Ge Bai

Ge Bai, PhD, CPA

Ge Bai is a Professor of Accounting at the Johns Hopkins Carey Business School and Professor of Health Policy and Management (joint) at the Bloomberg School of Public Health.  She is an expert on health care pricing, policy, and management.  Bai has written for the Wall Street Journal and published her studies in leading academic journals such as the New England Journal of Medicine, JAMA, Annals of Internal Medicine, and Health Affairs.  Her work has been widely featured in national media and used in government regulations and congressional testimony.  She is currently a visiting scholar at the Health Analysis Division of the Congressional Budget Office. Bai received her doctoral degree in Accounting from Michigan State University.

gbai@jhu.edu

Jeromie Ballreich

Jeromie Ballreich, PhD

Jeromie Ballreich is an Associate Research Professor and Director of the Master’s in Health Economics and Outcomes Research Program at the Johns Hopkins Bloomberg School of Public Health.  He is a health economist with a research focus on US pharmaceutical policy and economic evaluation. He has published in leading scientific journals and has testified before state legislators and the U.S. House of Representatives on pharmaceutical policy issues. He received his BA in Mathematics and Economics from Lafayette College, and a Masters and PhD in Health Economics from the Johns Hopkins Bloomberg School of Public Health.  Ballreich’s recent work has focused on pharmaceutical policy for cell and gene therapies; the intersection of drug prices, regulation, and innovation; and cost-effectiveness analyses alongside clinical trials.

Pineal Bareamichael, MD, MPH, MBA

Pineal Bareamichael is a Research Associate in the Department of Health Policy and Management at the Bloomberg School of Public Health.  His research focuses on leveraging policy reforms to accelerate equitable drug development for rare diseases and conditions with significant unmet therapeutic needs, as well as optimizing prescription drug accessibility, pricing, and reimbursement, particularly for high-cost specialty drugs in Medicare and commercial health insurance.  As a physician with an MPH and an MBA in Healthcare, Technology, and Innovation from Johns Hopkins University, he combines public health and clinical expertise with healthcare business acumen to drive evidence-based solutions that promote fair and affordable access to prescription drugs.

pbaream1@jhmi.edu

Robin Dranbauer

Robin Dranbauer is a Senior Administrative Coordinator within the Department of Health Policy and Management.  She manages all of the administrative and financial tasks associated with the JHDAAI project.  

rdranba1@jhu.edu

Jeremy A. Greene

Jeremy A. Greene, MD, PhD

Jeremy Greene is a Professor of the History of Medicine at the Johns Hopkins University School of Medicine. His area of clinical expertise includes internal medicine.  Greene serves as the Elizabeth Treide and A. McGehee Harvey Chair in the History of Medicine.  Greene’s research interests include the history of therapeutics, especially pharmaceuticals.  He also practices internal medicine at the East Baltimore Medical Center with admitting privileges to the Johns Hopkins University Hospital.  Greene earned his MD and PhD from Harvard University.  He completed his residency at Brigham & Women’s Hospital.  He serves on the Johns Hopkins University Press Faculty Editorial Board.  Greene’s research explores the ways in which medical technologies come to influence our understanding of what it means to be sick or healthy, normal or abnormal, on personal, regional, and global scales. Greene is the founding director of the Center for Medical Humanities and Social Medicine at Johns Hopkins University, Core Faculty in the JHDAAI, Associate Faculty at the Berman Institute of Bioethics, a co-Investigator in the Opioid Industry Documents Archive,  the Black Beyond Data Project, and the Sawyer Seminar in Precision and Uncertainty in a World of Data. He holds joint appointments in the Department of History of Science and Technology and the Department of Anthropology at the Krieger School of Arts and Sciences.

greene@jhmi.edu

Joseph F. Levy

Joseph F. Levy, PhD

Joseph Levy is an Assistant Professor of Health Policy and Management and a health economist who works on methods and policy to improve value-based decision making in healthcare.

jlevy@jhu.edu

Angela Liu

Angela Liu, PhD, MPH

Angela Liu is an Assistant Scientist in the Department of Health Policy and Management at the Bloomberg School of Public Health. Her research portfolio examines the impact of health policies on financial and healthcare outcomes related to the US healthcare system, specifically on payment, spending, access, and affordability in the Medicare and Medicare Advantage program.  She is engaged in the Johns Hopkins Drug Access and Affordability Initiative, where she evaluates pharmaceutical outcomes, and the Center for Health Systems and Policy Modeling, where her research takes a broader, systems approach.   Liu received a PhD in Health Policy and Management from the Johns Hopkins Bloomberg School of Public Health, a Master of Public Health from the University of Washington, and a Bachelor of Science in Biomedical Engineering from the University of Virginia.

aliu63@jhu.edu

Jenny Markell

Jenny Markell, BA

Jenny Markell is a PhD student at the Bloomberg School of Public Health in the Department of Health Policy and Management. Her research interests are in ensuring equitable access to health care and reducing health care costs for Americans, with a focus on pharmaceutical policy. She previously worked in the health care technology sector and in maternal and child health policy research. She received her BA from the University of Pennsylvania.
jmarkel4@jhu.edu

Ilina Odouard

Ilina Odouard, MPH

Ilina Odouard is a health services research PhD student at the Bloomberg School of Public Health in the Department of Health Policy and Management.  Her research investigates payment, affordability, and equitable access challenges associated with high-cost drugs.  Her work has been published in journals including JAMA, JAMA Neurology, the Journal of Managed Care and Specialty Pharmacy, and Value in Health.  She received her MPH from Johns Hopkins in 2023 and her BA in Neuroscience from Barnard College in 2018.  She previously worked as a life sciences and healthcare strategy consultant.

iodouar1@jhmi.edu

Joy Onyekachi Acha, PharmD, MPH, MBA

Joy Onyekachi Acha is a Research Program Coordinator in the Department of Health Policy and Management at the Johns Hopkins Bloomberg School of Public Health. Her work focuses on addressing challenges in drug supply chains, promoting sustainable pharmaceutical practices, and ensuring equitable access to medications. As a pharmacist, she integrates her clinical background with advanced public health and business expertise, holding master’s degrees from Johns Hopkins University.  Her contributions include leading projects to enhance pharmaceutical supply chain transparency and using data-driven approaches to inform policies that mitigate drug shortages and improve medication access. She is passionate about leveraging innovative strategies to address disparities in drug affordability and to advance global health outcomes.

jacha1@jhmi.edu

Joshua M. Sharfstein

Joshua M. Sharfstein, MD

Joshua Sharfstein is the Vice Dean for Public Health Practice and Community Engagement at the Bloomberg School of Public Health. Sharfstein is also professor of the practice in the Department of Health Policy and Management.  Sharfstein was appointed by Governor Martin O’Malley as Secretary of the Maryland Department of Health and Mental Hygiene in January 2011. As Secretary of DHMH, Sharfstein led efforts to modernize Maryland’s all-payer system for hospital payment.  In March 2009, President Obama appointed Sharfstein to serve as the Principal Deputy Commissioner of the U.S. Food and Drug Administration, the agency’s second highest-ranking position. From December 2005 through March 2009, Sharfstein served as the Commissioner of Health for the City of Baltimore, Maryland.  He began working on health and social policy matters as an advisor to longtime California Congressman Henry A. Waxman.  Sharfstein also serves as a member of the editorial board at the Journal of the American Medical Association (JAMA). Sharfstein received his MD from Harvard Medical School.

joshua.sharfstein@jhu.edu

Mariana P. Socal

Mariana P. Socal, MD, PhD

Mariana Socal is an Associate Professor  in the Department of Health Policy and Management.  Socal studies ways to make the US pharmaceutical market more competitive, delivering drugs of greater value for lower costs to the American people.  Socal is a physician with training in clinical neurology.  She holds a master’s of public policy from Princeton University and a PhD in health systems from the Bloomberg School of Public Health.
msocal1@jhu.edu

Michele Trieb, BA

Michele Trieb is a Senior Program Manager in the Department of Health Policy and Management.  She manages, coordinates, and facilitates data analytic projects and tasks for the JHDAAI project team.   She also maintains this website!

mtrieb2@jhu.edu

Antonio J. Trujillo

Antonio J. Trujillo, PhD

Antonio Trujillo is an applied health economist known for his work on enhancing medication accessibility across the U.S., Latin America, and globally. He concentrates on strategies to bolster market competition, ultimately broadening access to affordable generic drugs and biosimilars.  Trujillo’s research delves into the intricate realm of antitrust issues, exploring phenomena such as "pay for delay" and “mergers” to decipher the underlying factors contributing to generic market inefficiencies. His work offers a framework for researchers using the concept of fair pricing as a cornerstone for innovative drug pricing policy.  Currently, he explores policies to remove barriers impeding brand-to-brand competition and seeks ways to expedite the introduction of biosimilars. Trujillo analyzes policies to promote adoption of green inhalers and other green medical devices. He is the Director of the Master of Health Science in Global Health Economics program.
atrujil1@jhu.edu

Yang Wang

Yang Wang, PhD

Yang Wang is a research faculty in health economics and policy. His research interests include health care pricing and payment, health insurance market, and hospital finance.

ywang406@jhu.edu

Affiliate Project Team

Kelly E. Anderson

Kelly E. Anderson, PhD

Kelly Anderson is an Assistant Professor at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences.  She is a health policy researcher who applies econometric and descriptive quantitative methods to examine the effects of health insurance design and to model policy options to improve payment for prescription drugs. In particular, her drug pricing research focuses on payment for Medicare Part B drugs, out-of-pocket costs for insulin, and branded competition. She also studies differences in the cost and quality of care between traditional Medicare and Medicare Advantage. Anderson received a PhD in Health Policy and Management from the Bloomberg School of Public Health, as well as Master of Public Policy and Bachelor of Science in Biomedical Engineering degrees from the University of Virginia.  She has also consulted for federal health care agencies, state legislatures, and private companies regarding insurance design and payment policy.

kelly.e.anderson@cuanschutz.edu

Charles L. Bennett

Charles L. Bennett, MD, PhD

Charles Bennett is a hematologist and oncologist whose research focuses on preventing adverse drug events and improving drug safety. Bennett is studying ways to make drug information more consumer-friendly and creating new training tools for health care providers. Bennett has first-hand experience with commercializing technology and starting new companies. In 1998, he founded internationally known RADAR (Research on Adverse Drug Events And Reports) which investigates and disseminates information about adverse drug and device reactions (ADRs). His work has been awarded more than $4.2 million in federal research grants and has produced more than 250 publications. Bennett is currently affiliated with the Southern Network on Adverse Reactions (SONAR) which consists of co-investigators at fifty medical universities who have assisted with one or more evaluations of serious adverse drug reactions as part of two National Institutes of Health-funded pharmacovigilance grants.

bennettc@cop.sc.edu

Michael J. DiStefano

Michael J. DiStefano, PhD

Michael DiStefano is an Assistant Professor in the Center for Pharmaceutical Outcomes Research in the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of Colorado Anschutz Medical Campus. His research is primarily focused on health technology assessment, prescription drug policy, and direct-to-consumer pharmaceutical advertising. He is particularly interested in the ethical considerations that arise in each of these research areas. To advance research in these areas, DiStefano draws on both empirical research methods and conceptual and normative analysis. He completed his PhD in Health Policy & Management at the Bloomberg School of Public Health and also holds a master's degree in Bioethics from the University of Pennsylvania.

michael.j.distefano@cuanschutz.edu

Jason B. Gibbons, PhD

Jason Gibbons is an Assistant Professor at the University of Colorado Anschutz Medical Campus in the Department of Health Systems, Management and Policy.   His primary research interests include prescription drug utilization, effectiveness, and adherence, especially regarding mental health and substance use disorders.  He is also interested in issues related to drug pricing policy, patient spending on pharmaceuticals, and pharmaceutical antitrust.  Gibbons previously worked for the Bloomberg Overdose Prevention Initiative at Johns Hopkins University as a Postdoctoral Fellow to conduct program and policy evaluations to expand Medication for Opioid Use Disorder access, use, and equity.  He received his PhD in Health Services Organization and Policy (Economics Cognate) at the University of Michigan School of Public Health.

jason.gibbons@cuanschutz.edu

Manuel Hermosilla

Manuel Hermosilla, PhD

Manuel Hermosilla is an Associate Professor of Marketing at the University of Illinois Chicago (UIC) Business.   He is an applied microeconomist with expertise in drug innovation, drug consumption, clinical trials, and online pharmacies. Hermosilla’s research has been published in leading academic journals including Marketing Science, Management Science, and the Rand Journal of Economics. His work has been featured in national and international media outlets such as the New York Times, Vox, Axios, National Affairs, and the Hindustan Times. Hermosilla earned a PhD in Quantitative Marketing from the Kellogg School of Management at Northwestern University.

mher@uic.edu 

So Yeon Kang

So Yeon Kang, PhD, MBA

So Yeon Kang is an Assistant Professor of Health Management and Policy at the Georgetown School of Health. Her research focuses on issues at the intersection of health care payment policy, innovations, and business management. Her current research portfolio centers around prescription drug pricing policy, access and affordability and care delivery innovations under value-based payment reform. Kang’s research has been published in JAMA and Health Affairs and has been featured in media outlets including Forbes and Reuters. Prior to coming to academia, Kang gained experience in the pharmaceutical industry, having held positions in pricing and health technology assessment. Kang holds a PhD and an MBA from Johns Hopkins University.

sk2327@georgetown.edu

Joey Mattingly

Joey Mattingly, PharmD, MBA, PhD

Joey Mattingly has been in pharmacy for more than twenty years, with pharmacy operations experience as an entry-level technician, staff pharmacist, pharmacy manager, district manager for a major pharmacy chain, and private equity start-up director for a long-term care pharmacy operation serving multiple states. Mattingly left the private sector in 2014 to pursue an academic career while simultaneously earning his PhD in Health Services Research with a specific focus on pharmacoeconomics. Since 2014, Mattingly has developed a research portfolio that primarily focuses on drug pricing policy, and he has engaged policymakers at local, state, and federal levels, including serving as Speaker of the House of Delegates and Trustee for the American Pharmacists Association (APhA) from 2019‒2021. From November 2022 to April 2023, Mattingly served as an advisor to the Center of Medicare and Medicaid Services (CMS) to aid in the implementation of the new “Drug Price Negotiation Program” authorized by Congress through the Inflation Reduction Act. Most recently, he was named a Research Fellow for the National Association of Insurance Commissioners (NAIC) to help inform policy on pharmacy benefit manager practices.

joey.mattingly@pharm.utah.edu

Thomas J. Moore, AB

Thomas Moore has spent the last 20 years researching and writing about the risks and benefits of prescription drugs and their regulation.  He is a faculty associate at the Center for Drug Safety and Effectiveness, Johns Hopkins University Bloomberg School of Public Health and an associate in the Johns Hopkins Drug Access and Affordability Initiative.  He is also a Professorial Lecturer in the Department of Epidemiology at the George Washington University Milken Institute School of Public Health.  For more than 10 years he was a senior scientist for the non-profit Institute for Safe Medication Practices and project director of QuarterWatch, a publication that monitored all adverse drug events reported to the Food and Drug Administration. He also undertakes consulting assignments doing business as Drug Safety Research.  He is author of 4 books about medicine and pharmaceutical drugs and a coauthor of more than 30 peer reviewed publications. 

tmoore86@jhmi.edu